News | April 04, 2011| Dave Fornell

Antioxidant Formula Prior to Radiation Exposure May Prevent DNA Injury

April 4, 2011 – A unique formulation of antioxidants taken orally before imaging with ionizing radiation minimizes cell damage, noted researchers at the Society of Interventional Radiology’s 36th Annual Scientific Meeting in Chicago. In what the researchers say is the first clinical trial of its kind, as much as a 50 percent reduction in DNA injury was observed after administering the formula prior to CT scans.

“In our initial small study, we found that pre-administering to patients a proprietary antioxidant formulation resulted in a notable dose-dependent reduction in DNA injury,” said Kieran J. Murphy, M.D., FSIR, professor and vice chair, director of research and deputy chief of radiology at the University of Toronto and University Health Network, Toronto, Canada. “This could play an important role in protecting adults and children who require imaging or a screening study.”

“Pre-administering this formula before a medical imaging exam may be one of the most important tools to provide radioprotection and especially important for patients in the getting CT scans,” said Murphy. The study’s data support the theory about a protective effect during these kinds of exposure.

“There is currently a great deal of controversy in determining the cancer risks associated with medical imaging exams. Although imaging techniques, such as CT scans and mammograms, provide crucial and often life-saving information to doctors and patients, they work by irradiating people with X-rays, and there is some evidence that these can, in the long run, cause cancer,” explained Murphy. The researchers responded to this patient need by exploring a way to protect individuals from these potentially harmful effects. This may be of importance to interventional and diagnostic radiologists and X-ray technologists who have occupational exposure also.

The small study showed that even though many antioxidants are poorly absorbed by the body, one particular mixture was effective in protecting against the specific type of injury caused by medical imaging exams. People are 70 percent water, and X-rays collide with water molecules to produce free radicals. These groups of atoms with an unpaired number of electrons are dangerous when they react with cellular components, causing damage and even cell death. Free radicals can go on to do damage by directly ionizing DNA and other cellular targets. The research team evaluated whether a special combination of antioxidants have an ability to neutralize these free radicals before they can do damage.

“Our intent was to develop an effective proprietary formula of antioxidants to be taken orally prior to exposure that can protect a patient’s DNA against free radical mediated radiation injury, and we have applied to patent this formulation and a specific dose strategy,” said Murphy.

The experiments measured DNA damage as a surrogate marker for DNA injury. Blood was drawn from two study volunteers in duplicate, creating four individual tests per data point. DNA strand breaks are repaired by a big protein complex that binds to the site of the damage. The researchers labeled one of the proteins with a fluorescent tag. Then, under a powerful 3-D microscope, the DNA is examined for signs of repair. The more repair that is seen, the more DNA damage must have been done by the CT scan to initiate that repair. The experiments showed a reduction of DNA repair in the treatment group, which means that there was less DNA injury as a result of pre-administering the antioxidant mixture.

The researchers concede that this is a small study and that a lot more research needs to be done. However, these initial results point toward a positive future for this kind of treatment. The group says the next step is a clinical trial in Toronto.

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init